Segall Bryant & Hamill LLC Buys 49,856 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Segall Bryant & Hamill LLC boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 355,176 shares of the biopharmaceutical company’s stock after acquiring an additional 49,856 shares during the period. Segall Bryant & Hamill LLC’s holdings in Halozyme Therapeutics were worth $20,330,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Congress Asset Management Co. increased its stake in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after buying an additional 856,200 shares in the last quarter. Boston Trust Walden Corp bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $23,211,000. Swedbank AB purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth $13,927,000. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after acquiring an additional 270,579 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Morgan Stanley upped their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Benchmark reaffirmed a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Up 2.1 %

NASDAQ:HALO opened at $45.76 on Thursday. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a market capitalization of $5.82 billion, a PE ratio of 15.15, a P/E/G ratio of 0.42 and a beta of 1.29. The firm’s 50-day moving average price is $55.15 and its 200-day moving average price is $53.48. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $39,988,802.96. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 60,000 shares of company stock worth $3,425,000. 2.70% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.